DavidRFreyerDO

Pediatric Hematology & Oncology • Los Angeles, CA

Professor, Pediatrics, USC School of Medicine

Join to view full profile

Dr. Freyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Freyer's full profile

Already have an account?

Office
1441 Eastlake Ave
Los Angeles, CA 90089
Phone+1 323-865-3000

Fax+1 323-361-7128

Education & Training

University of MichiganFellowship, Pediatric Hematology/Oncology, 1985 - 1988
Rush University Medical CenterResidency, Pediatrics, 1982 - 1985
Des Moines University College of Osteopathic MedicineClass of 1981

Certifications & Licensure

CA State License 2007 - 2025
MI State License 1985 - 2009
IL State License 1982 - 1987
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Start of enrollment: 2007 May 01
Completed
Phase 3
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Start of enrollment: 2008 Jun 23
Completed
Phase 3
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
Completed
Phase 2
LIFE Cancer Survivorship Database for Pediatric Cancer Start of enrollment: 2009 Feb 01
Recruiting
NAC to Prevent Cisplatin-induced Hearing Loss Start of enrollment: 2016 Mar 01
Completed
Phase 1
Childhood Cancer Survivor Study Start of enrollment: 1995 Jan 05
Recruiting
Roles: Contact, Principal Investigator
Childhood Cancer Survivor Study Start of enrollment: 1995 Jan 05
Recruiting
Roles: Contact, Principal Investigator
The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer Start of enrollment: 2019 Apr 15
Active, not recruiting
Not Applicable
Roles: Contact, Principal Investigator
Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer Start of enrollment: 2023 Apr 14
Recruiting
Not Applicable
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

30 citations
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
Eric J. Chow, Richard Aplenc, Lynda M. Vrooman, David R. Doody, Yuan-Shung Huang
Cancer. 2021-10-13
15 citations
Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
Eric J Chow, Sanjeev Aggarwal, David R Doody, Richard Aplenc, Saro H Armenian
Journal of Clinical Oncology. 2023-04-20
13 citations
Depressive Symptoms and Quality of Life Among Adolescent and Young Adult Cancer Survivors: Impact of Gender and Latino Culture.
Anamara Ritt-Olson, Kimberly A. Miller, Lourdes Baezconde-Garbanati, David R. Freyer, Cynthia N Ramirez
Journal of Adolescent and Young Adult Oncology. 2018-06-01

Journal Articles

Treatment Strategies for Adolescent and Young Adult Patients with Acute Myeloid Leukemia
John T Horan, David R Freyer, Blood

Press Mentions

Study Creates National Benchmark for Cancer Survivorship CareAugust 22nd, 2024
American College of Surgeons Launches Cancer Survivorship Services SurveyMay 4th, 2023
Hearing Loss Therapy: Fennec Pharma Gets USFDA Nod for PEDMARKSeptember 22nd, 2022
Join now to see all